Category: Q&A

Excellence, Cooperation, and Passion Come Together to Serve the Scientific Community. Q&A with Dr. Peter O’Toole, Director of the Bioscience Technology Facility, University of York.

Dr. Peter O'Toole, Ph.D., is the director of the Bioscience Technology Facility at the University of York in England, where he established and still leads the Imaging and Cytometry Laboratory, one of the top bioscience technology facilities in Europe. His lab is an...

/ August 3, 2020

Statistically Significant Results without the Headache. Q&A with Sarah Church, PhD, Senior Scientist at NanoString.

Talking to Sarah, whether during social gatherings or within the office walls, is always a pleasure. Dr. Church is a Senior Scientist at NanoString, and one of the warmest people you can run into in the hallway. She is also...

/ July 27, 2020

Spotlight on a CRO: Interview with the Team of Scientists behind NeoGenomics Pharma Services.

NeoGenomics is a cancer diagnostics and pharma services company serving pharmaceutical companies and academic centers. They specialize in diagnostic, prognostic and predictive testing using the most innovative technologies. The company opened its doors in 2002 in Fort Myers, FL, and...

/ July 8, 2020

Going Beyond PDL-1. Q&A with Dr. Nina Radosevic- Robin, MD.

Dr. Nina Radosevic-Robin, MD, is a Board-Certified Surgical/Molecular Pathologist at Centre Jean Perrin, a Sr. Scientist within the Unit 1240 of French National Institute for Medical Research (INSERM), and a Lecturer in Molecular Oncology and Protein Science at the University...

/ June 22, 2020

Why is Digital Spatial Profiling Critical to Studying Sarcomas? Q&A with Dr. Troy McEachron, Ph.D

“Whereas the EWS specimens tended to have very simple genomes, the osteosarcoma specimens looked like a hand grenade had gone off in the genome. These were the most fragmented and complex genomes I had ever seen”. Troy McEachron, Ph.D The first...

/ June 15, 2020